The Latest Breaking News from RAD

The majority of adults in the UK are not aware there is no legal requirement for dance teachers to have relevant teaching qualifications.

Consumer staples companies are known for performing relatively well during a market turmoil because of inelastic demand for their products. However, Wall Street analysts expect fundamentally weak consumer staples stocks Japan Tobacco (JAPAY), National Beverage (FIZZ), Grocery Outlet (GO), and Rite Aid (RAD) to decline more than 10% in the…

Rite Aid (RAD) shares soared last week after the company reported stronger-than-expected first-quarter revenue growth and issued an upbeat sales forecast. However, given the company’s increasing losses and projected interest rate hikes, is it worth buying the stock now? Let’s find out.

Rite Aid Corp (NYSE:RAD) has reported Q1 FY23 sales of 6.01 billion, down 2.4% Y/Y, beating the consensus of $5.75 billion.  The company reported an EPS loss of $(0.60) compared to an income of $0.38 a year ago, driven by non-cash impairment charges and cycling prior-year COVID vaccination benefit. Retail Pharmacy Segment…

Heritage Cannabis Holdings Corp. (OTCQX: HERTF) (CSE:CANN) has signed a definitive agreement for the supply of its products to a major LP for sale on its medical platform.

Whether its jerk, rice and peas or curry goat, the city is brimming with great Caribbean food

Leading pharmaceutical retailer Rite Aid (RAD) shares jumped last week thanks to its stronger-than-expected fourth-quarter revenue growth driven by an increase in same-store and pharmacy sales. Although the company’s strategic initiatives to boost membership should bode well for the stock, its struggling Elixir business and expanding losses could lead to…

Rite Aid (NYSE:RAD) reported its Q4 earnings results on Thursday, April 14, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Rite Aid missed estimated earnings by 191.07%, reporting an EPS of $-1.63 versus an estimate of $-0.56.

Rite Aid Corp (NYSE:RAD) has reported Q4 FY22 sales of 6.06 billion, +2.5% Y/Y, beating the consensus of $5.95 billion. The Company reported an EPS loss of $(1.63) compared to $(0.78) a year ago. The growth is driven by growth in the Retail Pharmacy, partially offset by a decline in the Pharmacy…

Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers, and following industry trends.

  U.S. stocks pared losses, with the Dow Jones and S&P 500 turning positive toward the end of trading on Thursday.